Radioimmunodetection studies of prostate and T-cell lymphoma tumors using In-111 labeled monoclonal anti-tumor antibodies

The purpose of these studies was to determine if prostate carcinoma (PC) and cutaneous T-cell lymphoma (CTCL) could be detected using the In-lll- MoAbs described in this paper. Murine IgG MoAbs were developed against prostatic acid phosphatase (PAP) and to an antigen present on human T-cells. The MoAbs were labeled with In-lll by a bifunctional chelation technique and administered (ad) intravenously to patients (PT) with PC and CTCL respectively. One mg or less of each MoAb was labeled with 1.5-5.0 mCi of In-111. Normal prostate tissue was visualized in 3 of 5 PT and 5 of 12 bone metastases were detected in a PT with PC. Outstanding definitions of lymph nodes was achieved in CTCL. The sequence of administration markedly altered the invivo kinetics of the IN-111-MoAb. Some toxicity was observed in CTCL patients but not in PT with PC. The authors conclude that the above MoAbs will target tumor and that the sequence and to some extent quantities of MoAb has an affect on the pharmacokinetics and tumor uptake of these two MoAbs